Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 29 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

21%

6 trials in Phase 3/4

Results Transparency

29%

5 of 17 completed with results

Key Signals

5 with results100% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (9)
P 1 (6)
P 2 (4)
P 3 (6)

Trial Status

Completed17
Active Not Recruiting5
Recruiting4
Unknown2
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT04544449Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04918225CompletedPrimary

Motor Asymmetry in Progressive Multiple Sclerosis Patients

NCT05122559Phase 2Active Not Recruiting

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

NCT05359653Phase 1Recruiting

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT06138132Phase 1Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

NCT04035005Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT03455582Not ApplicableActive Not RecruitingPrimary

Cognition Evolution and MRI Markers in PPMS Patients on 2 Years

NCT06526364Recruiting

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)

NCT06683612Phase 1Completed

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

NCT06900192Phase 1Not Yet Recruiting

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

NCT06384976Phase 2Active Not RecruitingPrimary

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

NCT06436131Not ApplicableCompletedPrimary

The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis

NCT05663853Completed

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

NCT02688985Phase 3Completed

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT05496881Not ApplicableUnknownPrimary

Exercise Effects in Multiple Sclerosis

NCT05204459Recruiting

MS-ResearchBiomarkerS

NCT01194570Phase 3CompletedPrimary

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT03679468Not ApplicableCompletedPrimary

Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation

NCT02988401Phase 1Completed

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02305264Not ApplicableCompleted

Imaging of Intracerebral Inflammation in MS

Scroll to load more

Research Network

Activity Timeline